Vaccine Breaking News

Vaccine breaking news brought to you by Precision Vaccinations.

Oct 7, 2022 • 3:06 am CDT
U.S. Dept of State

Currently, vaccines and treatments are approved by the U.S. Food and Drug Administration (FDA) targeting the Ebola virus disease (EVD) caused by the Zaire Ebolavirus, but not the Sudan species. 

As of October 7, 2022, the FDA, the U.S. CDC, and the World Health Organization are collaborating on developing Sudan Ebolavirus vaccines and treatments for use in Uganda.

Vaccine candidates focused on the Sudan Ebolavirus have conducted early-stage clinical trials and are expected to proceed with experimental human studies in the Republic of Uganda in October 2022.

Uganda's ongoing Sudan Ebolavirus outbreak has expanded with a case-fatality rate of over 40%.

The U.S. CDC has issued a Level 2 Travel Health Notice due to Ebolavirus disease in the following districts:  Mubende, Kassandra, Kyegegwa, Kagadi, and Bunyangabu.

Regarding Zaire Ebolavirus, the U.S.FDA approved the Ervebo® vaccine on December 19, 2019.

And a two-dose vaccine regimen of a different vaccine was used under a research protocol in 2019 during an Ebola outbreak in the Democratic Republic of the Congo.

The two doses of this vaccine use different vaccine components, Zabdeno (Ad26.ZEBOV) and Mvabea (MVA-BN-Filo).

This regimen requires an initial dose and a booster dose 56 days later. 

Additionally, there are currently two treatments* approved by the U.S. FDA to treat EVD in adults and children caused by the Zaire ebolavirus.

These monoclonal antibody treatments (mAbs) bind to a portion of the Ebola virus's surface called the glycoprotein, which prevents the virus from entering a person's cells.

The first mAbs was approved in October 2020, Inmazeb™ is a combination of three monoclonal antibodies.

The second single mAbs, Ebanga™, was approved in December 2020.

mAbs are proteins produced in a lab or manufacturing facility that act like natural antibodies to stop a germ, such as a virus, from replicating after it has infected a person.

Other Ebola outbreak news is posted at Vax-Before-Travel.

Oct 6, 2022 • 11:27 am CDT
by Fernando Zhiminaicela

Massachusetts-based CSL Seqirus recently announced results from the preclinical studies of the company's self-amplifying messenger RNA (sa-mRNA) influenza vaccine candidates.

The data indicates that the sa-mRNA influenza vaccine candidates produced a potent, cross-reactive immune response against pandemic and seasonal influenza strains, A(H5N1) and A(H1N1).

Unlike standard mRNA vaccines, sa-mRNA instructs the body to replicate mRNA, amplifying the amount of protein made.

This could enable vaccine manufacturers to potentially develop more effective vaccines with a smaller dosage and with lower rates of reactogenicity, underscoring the value in both pandemic and seasonal settings.

"These preclinical data show the potential of sa-mRNA technology to protect against pandemic and seasonal influenza in one vaccine dose," said Ethan Settembre, Ph.D., Vice President, Research, CSL R&D Seqirus Vaccines Innovation Unit and study author, in a press release on October 5, 2022.

"As we look toward initiating our Phase 1 clinical trials in the near future, these data are an encouraging testament to the value of pursuing innovative vaccine technology platforms like sa-mRNA."

These data were published in Molecular Therapy – Methods and Clinical Development (Oct. 3/22)

Influenza is a common, contagious respiratory disease that may cause severe illness and life-threatening complications in some people, says the U.S. CDC.

The CDC recommends annual vaccination for individuals aged six months and older who do not have any contraindications get vaccinated by the end of October 2022.

Various influenza vaccines are available at clinics and local pharmacies in the USA.

Additional flu shot news for 2022 is posted at

Oct 6, 2022 • 6:54 am CDT
by Thorsten Frenzel

Based on technology developed at Washington University in St. Louis, MO, a nasal vaccine for COVID-19 is on the path to becoming available in the U.S., Europe, and Japan.

Nasal vaccination is thought to provide greater protection against the virus than current injectable vaccines.

The advantage of the nasal vaccine is that it delivers a boost to immunity in the nose and upper respiratory tract, right where the virus enters the body, thereby potentially preventing infections altogether.

The university has licensed the rights to Ocugen Inc., a U.S.-based biotechnology company.

Ocugen intends to work closely with the U.S. government to initiate clinical trials and is also interested in the potential for the nasal vaccine to be a universal booster.

"Despite the many challenges of a global pandemic, our accomplished, dedicated faculty have continued to push the boundaries of discovery," said Dedric Carter, Ph.D., Washington University's vice chancellor for innovation and chief commercialization officer, in a press release on October 4, 2022.

The nasal vaccine was co-developed by Washington University scientists David T. Curiel, MD, Ph.D., and Michael S. Diamond, MD, Ph.D., with members of their laboratories. 

"In recent months, we have seen COVID-19 continue to spread — despite high levels of vaccination the U.S., Europe, and Japan have achieved," Diamond commented.

"Because the vaccine can be delivered directly into the nose, it is specifically designed to block infection at the portal of virus entry. As a result, we believe it may help prevent transmission and protect against new COVID-19 variants."

The Washington University nasal vaccine technology was previously licensed to Bharat Biotech International Limited in 2020 for development in India and limited parts of the world.

In September 2022, Indian health authorities approved the iNCOVACC (BBV154) nasal vaccine for emergency use, making it the world's first intranasal vaccine for COVID-19 to be approved.

Bharat Biotech's Covaxin™ whole virion, inactivated COVID-19 vaccine, has been licensed to various countries. However, as of October 6, 2022, the U.S. FDA has not issued authorization.

Note: This announcement was manually curated for clarity and mobile readership.

Oct 5, 2022 • 1:56 pm CDT
by Gerhard

The European Centre for Disease Prevention and Control (ECDC) recently reported that Europe's 2021–2022 highly pathogenic avian influenza (HPAI) epidemic season was the largest ever observed. 

As of October 3, 2022, the latest ECDC data shows that 48 million birds were culled in 37 European countries.

This news is vital since HAPI can sporadically infect humans, causing mild to very severe diseases.

"Thankfully, there have been no human infections during the recent outbreaks of avian influenza in the EU/EEA," said Andrea Ammon, ECDC Director, in a related press release. 

"However, several groups of people, mainly those working in the animal sector, are at increased risk of exposure to infected animals."

"Vigilance is needed to identify infections with influenza viruses as early as possible and to inform risk assessments and public health action," she added.

Since 2003, more than 860 human infections with HPAI A(H5N1) viruses have been reported to the World Health Organization (WHO).

With about 53% of those HAPI patients resulting in fatalities.

Ancestors of HPAI A(H5N1) viruses first emerged in southern China in 1997.

According to the U.S. CDC, the Asian lineage H5N1 and H7N9 have caused the most human infections. 

Internationally, 54 countries reported an H5N1 outbreak in birds in 2021 and 2022.

The Eurasian H5N1 strain first appeared in North America in January 2022 and has affected poultry/birds in 40 states and led to the loss of about 47 million birds as of October 3, 2022. 

The CDC says, 'the public health risk associated with these avian influenza detections in birds remains low.'

However, the CDC did confirm one H5 human infection in Montrose County, Colorado, in April 2022.

The CDC says annual flu shots do not protect people from avian influenza (bird flu) pandemic infections.

The U.S. FDA has approved a bird flu pandemic vaccine that would distribute if a person-to-person outbreak occurs.

The FDA has authorized CSL Seqirus' Audenz™ monovalent cell-based vaccine for persons at increased risk of exposure to the influenza A virus H5N1 subtype.

Additional avian influenza vaccine news is posted at

Oct 4, 2022 • 4:00 pm CDT

The U.S. Food and Drug Administration (FDA) released important information about the risk of COVID-19 due to specific SARS-CoV-2 virus variants not neutralized by Evusheld™ on October 3, 2022.

Evusheld, a Long-Acting antibody combination (tixagevimab co-packaged with cilgavimab), is currently the only pre-exposure prophylaxis (PrEP) option for COVID-19.

The FDA continues to recommend Evusheld as an appropriate option for PrEP to prevent COVID-19, in combination with other preventative measures like getting vaccinated and boosted as recommended, as Evusheld still offers protection against many of the currently circulating variants and may offer protection against future variants. 

The FDA says healthcare providers should inform patients of this risk and advise patients who develop signs or symptoms of COVID-19 to test for SARS-CoV-2 infection and promptly seek medical attention, including starting treatment for COVID-19, as appropriate if they test positive.   

Detailed neutralization data can be found in the revised authorized Fact Sheet for Healthcare Providers.

The FDA issued an emergency use authorization for Evusheld on December 8, 2021. Since then, about 860,000 Evusheld doses have been distributed in the U.S.

Evusheld has also been authorized in Europe, the U.K., and other countries.

Additional mAbs products targeting COVID-19 are listed at

Oct 4, 2022 • 3:19 pm CDT
by Gerd Altmann

California-based Vir Biotechnology, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA) awarded Vir a multi-year contract with the potential for up to $1 billion to advance the development of a full portfolio of innovative solutions to address influenza and potentially other infectious disease threats.

As part of BARDA’s ongoing effort to prepare and respond to public health emergencies, the agency will initially invest approximately $55 million for the continuing and rapid development of VIR-2482, an investigational prophylactic monoclonal antibody (mAb) designed to protect against seasonal and pandemic influenza.

In vitro, VIR-2482 has been shown to cover all significant strains of influenza A that have arisen since the 1918 Spanish flu pandemic.

This includes a Phase 2 pre-exposure prophylaxis trial expected to begin in the second half of 2022, with initial data anticipated in mid-2023. 

Bolyn Hubby, Ph.D., EVP, and chief corporate affairs officer at Vir Biotechnology, commented in a press release on October 4, 2022, “Today’s announcement represents the culmination of our ongoing dialogue with the U.S. government around our shared interest in protecting society from global infectious disease threats, and we are thrilled to embark on this broad, multi-year collaboration.”

The balance of the award is subject to BARDA exercising up to 12 options in further support of the development of pre-exposure prophylactic mAb, including and beyond VIR-2482 for the prevention of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential.

VIR-2482 has the potential to overcome the limitations of current flu vaccines and lead to meaningfully higher levels of protection due to its broad strain coverage and because it does not rely on an individual to create their protective antibody response.

VIR-2482, which incorporates Xencor’s Xtend™ Technology, also has been half-life engineered, so a single dose has the potential to last the entire influenza season.

Pandemic influenza is a contagious airborne respiratory disease, which is unpredictable in timing and severity and for which humans have little or no immunity.

Four influenza pandemics have occurred over the past century, the most severe being the 1918 “Spanish flu,” which is estimated to have caused up to 50 million deaths worldwide.

Under the collaboration agreement signed with GlaxoSmithKline (GSK) in 2021, GSK has an exclusive option to lead the post-Phase 2 development and commercialization of VIR-2482.

Please visit the latest Zoonotic Influenza News for additional information on Avian, Pandemic, and Swine influenza.

Oct 4, 2022 • 4:58 am CDT
U.S. CDC Uganda

Ebola was discovered in 1976 when two independent hemorrhagic fever outbreaks occurred in central Africa, one near the Ebola River in the country of Zaire (now the Democratic Republic of the Congo), and the second in South Sudan, wrote GAVI on October 3, 2022.

Scientists later discovered that these outbreaks were caused by genetically distinct and often deadly viruses: Zaire ebolavirus and Sudan ebolavirus.

Both Ebola viruses are transmitted through direct contact with the blood or body fluids of someone infected with or who died from Ebola.

While Zaire ebolavirus has been responsible for more outbreaks and human fatalities of Ebola than any other strain, an outbreak of Sudan ebolavirus started in Uganda in September 2022.

The Ministry of Health of Uganda has declared an Ebola outbreak in several districts in Uganda.

As of yesterday, the Ministry of Health- Uganda Tweeted:

  • Total cases: 62 (43 conf.)
  • Total deaths: 28 (9 conf.)
  • Case fatality rate (all cases): 45%

There are two licensed Zaire Ebola vaccines, Merck’s ERVEBO vaccine and Johnson and Johnson’s Zabdeno/Mvabea vaccine.

“Based on available evidence, the ERVEBO vaccine – used in the recent responses against Ebola outbreaks – will not provide cross-protection against the Sudan virus disease,” the WHO recently confirmed.

The good news is that several vaccine candidates against Sudan ebolavirus have already undergone Phase 1 human trials.

The WHO has said the risk of international spread could not be ruled out at this stage.

As of October 3, 2022, the U.S. CDC issued a Watch - Level 1, Practice Usual Precautions, travel advisory.

The CDC says travelers to this area (Uganda) should avoid contact with sick people and blood or body fluids from all people.

Moreover, travelers should isolate themselves immediately and seek medical care if they develop signs and symptoms of Ebola. 

Other Ebola outbreak news is posted at

Oct 3, 2022 • 6:01 pm CDT
by Gerd Altmann

Denmark-based Bavarian Nordic A/S announced today an agreement with a Latin American country for the supply of the two-dose JYNNEOS®  (MVA-BN, IMVANEX®) monkeypox vaccine.

This is Bavarian Nordic's first bilateral supply agreement for the JYNNEOS in Latin America, outside the scope of the contract entered with the Pan American Health Organization (PAHO) in August 2022. 

Paul Chaplin, President and CEO of Bavarian Nordic, said in a press release on October 3, 2022, "Vaccinating against monkeypox has been a key element in tackling the outbreak."

"And we are extremely pleased to reinforce our commitment to the region and increase the availability of our vaccine through additional supply agreements."

Through PAHO's Revolving Fund for Access to Vaccines, the unnamed Latin American country will gain access to JYNNEOS vaccines in October, and deliveries under the bilateral agreement will start in December 2022.

Separately, the PAHO has requested additional JYNNEOS doses to be delivered before the end of 2022 to expand access for its member countries.

The U.S. CDC confirmed on September 27, 2022, that 803,596 doses had been administered in reporting U.S. Jurisdictions.

JYNNEOS is the only U.S. FDA-approved non-replicating smallpox and monkeypox vaccine for military and non-military use.

However, it is not commercially available in the USA.

Monkeypox is a rare disease discovered in 1958 caused by infection with the monkeypox virus (MPXV), which is part of the same family of viruses that causes smallpox.

Monkeypox symptoms are similar to smallpox symptoms, but milder, says the CDC.

The CDC has reported 26,049 monkeypox virus cases in the USA and two related fatalities since May 2022.

Other MPXV outbreak news is posted at Monkeypox Today.

Oct 3, 2022 • 3:48 pm CDT
Sierra Leone introduces HPV vaccine

In a move to protect adolescent females from cervical cancer, the Government of Sierra Leone today launched a Human Papillomavirus (HPV) vaccination campaign, intending to immunize 153,991 ten-year-old girls.

Sierra Leone joins the group of regional pacesetters introducing the HPV vaccine into routine immunization programs as a critical strategy to prevent mortality and morbidity due to cervical cancer.

More than 55% of the 194 WHO Member States have introduced HPV vaccination.

“The Government of Sierra Leone wholeheartedly welcomes the introduction of the HPV vaccination drive and urges all to support girls ten years of age to be vaccinated and thus preventing them from cervical cancer and its consequences during their entire lives,” said Dr. Austin Demby, Minister of Health and Sanitation, in a press release issued on October 3, 2022.

According to the Sierra Leone Cancer registry, cervical cancer is the second most common and number one killer of all cancers among women aged between 14 and 44.

And in 2021, approximately 504 new cases of this deadly cancer were diagnosed.

“We are in the era where no one should suffer or die from diseases that are preventable with the use of vaccines. And, as we make these lifesaving services accessible to safeguard the health of women and girls, we are also contributing to empowering the individual, the community, as well as enhancing the sustainable social and economic development of the nation”, says Dr. Steven Velabo Shongwe, WHO Representative in Sierra Leone.

“We urge authorities and parents to ensure that their girls are protected against the distress of cervical cancer by protecting them against HPV at an early age.”

Additional HPV vaccination news is posted at

Oct 3, 2022 • 6:43 am CDT
by Namenibe Y. Lamboni

A new statistical report co-authored with the U.K. Health Security Agency (UKSHA) found childhood vaccination coverage statistics decreased for England in 2021-22.

Announced on September 29, 2022, data related to the 13 routine vaccinations offered to all children up to five years decreased from 0.2% to 1.1% last year.

For example, the proportion of children who received their second dose of the measles-mumps-rubella (MMR) vaccine by age five in 2021-22 was 85.7%, a decrease from 86.6% the year before.

Prof Helen Bedford, Professor of Child Public Health, Institute of Child Health, UCL, commented in a separate news article, "The U.K. has a highly successful childhood vaccination program which resulted in many once-common diseases such as measles, becoming vanishingly rare."

"Due to the measures brought in to reduce social contact during the pandemic, we saw infection rates drop to extremely low levels."

"However, these infections have not gone away."

"The reported decline in vaccine uptake in 21/22 compared with previous years is of great concern."

"However, this decline comes as little surprise given the difficulties for some parents accessing immunization services during the pandemic."

"But now we are back to normal, leaving us with the double whammy of many children being unprotected and the inevitability of disease rates increasing."

"In this situation, as night follows day, significant disease outbreaks are likely."

"Measles disease is a particular concern as it is so highly infectious that any small decline in vaccine uptake results in outbreaks."

"Fortunately, it is never too late to be vaccinated."

"No child needs to face the potentially serious consequences of a vaccine-preventable disease," concluded Bedford's comments on September 29, 2022.

The U.S. CDC reported for the 2020-2021 school year, measles vaccination coverage was 93.9% for two doses of the MMR vaccine. 

Furthermore, the CDC says most measles cases in the U.S. originate from international travel. Therefore, it is critical for all international travelers to be protected against measles, regardless of their destination.

As of September 1, 2022, a total of 13 measles cases were reported by five U.S. jurisdictions this year.

The MMR vaccine protects against all three diseases, and two doses offer 97% protection against measles.

The MMR®-II vaccine is available at most clinics and pharmacies in the USA.

And the U.S. FDA Approved the Priorix vaccine in June 2022 for individuals one year of age and older.

Other measles vaccine news is posted at

Note: This article was manually translated and curated for mobile readership.

Oct 3, 2022 • 4:19 am CDT
by Oberholster Venita

The Indonesian Food and Drugs Agency (Badan POM) recently issued an Emergency Use Authorization (EUA) for AWcorna, the Walvax-Abogen SARS-CoV-2 mRNA vaccine.

The AWcorna vaccine was developed in China by Walvax Biotechnology Co., Ltd. and Suzhou Abogen Biosciences Co., Ltd., and is authorized for adults as a two-dose primary (0.5 mL each) and those who have completed the primary series with CoronaVac® vaccines at least six months prior.

The companies announced on September 30, 2022, clinical trial results indicate the efficacy of AWcorna against symptomatic wild-type SARS-CoV-2 infection was 83.58%, and the efficacy against the Omicron variant was 71.17% in preventing moderate COVID-19 diseases.

And the administration of AWcorna in the general population showed good safety and tolerability, the most commonly reported symptoms of side effects were fever, pain at the injection site, fatigue, muscle pain, headache, chills, swelling, and itching.

"We are delighted to share the good news with everyone that obtaining the Indonesian EUA is a remarkable achievement in the commercialization stage of this product."

"Furthermore, as a proprietary mRNA vaccine independently developed in China, it is indeed proof of the effectiveness of our mRNA technology platform," commented Mr. Li Yunchun, Chairman, Walvax Biotechnology Co., Ltd., in a press release.

"Indonesia is the country with the fourth largest population and most Muslim in the world, so we believe the certified halal vaccine will be a safe, effective option for Indonesian people, which is also in alignment with their culture."

"This is the first step, and we are hoping to see more families across the country and the rest of the globe protected, which is a shared goal for us all."

Indonesia also uses mRNA COVID-19 vaccines produced by Pfizer-BioNTech and Moderna Inc.

Note: This announcement was manually translated and curated for mobile readers.

Sep 30, 2022 • 4:16 pm CDT
Texas Influenza Surveillance

The Texas Department of Health and Human Services (TDHHS) latest influenza surveillance report suggests the 2022-2023 flu season may have arrived. After a very quiet 2021-2022 flu season, three Texas Regions 7, 8, and 11, are now influenza hot spots.

This week's TDHHS report indicates the percentage (3.56%) of specimens testing positive (6749/240) for influenza increased.

The good news, as of September 30, 2022, is there have been no influenza-associated pediatric mortalities reported in Texas during the 2021-2022 flu season.

This contrasts with data released today by the U.S. CDC.

A total of (39) influenza-associated pediatric deaths occurring during the 2021-2022 season have been reported to CDC.

This data compares with (1) influenza-associated pediatric death during the 2020-2021 season and (199) during the 2019-2020 season.

The CDC suggests most people get the annual flu shot early in the season, with a booster dose later in the season if needed.

Various influenza vaccines are available at most clinics and pharmacies in the USA.

Additional flu shot news is posted at

Sep 30, 2022 • 9:03 am CDT
by F. Muhammad

Indonesia-based PT Bio Farma confirmed today it is ready to produce 20 million doses of the IndoVac COVID-19 vaccine in 2022 and 100 million doses by 2024. This innovative vaccine has already received emergency use authorization in Indonesia as an adult primary vaccine.

IndoVac is a recombinant protein-based vaccine technology created and engineered in Houston, Texas, by the Texas Children’s Hospital Center for Vaccine Development (CVD) and Baylor College of Medicine.

PT Bio Farma, is the largest pharmaceutical holding company in Indonesia. licensed IndoVac from BCM Ventures.

Indonesia is seeking Halal Certification for the vaccine. IndoVac successfully completed an audit from the Indonesian Ulema Council Food and Drug Analysis Agency, and the Halal Certification Agency of the Religious Affairs Ministry is expected to grant their approval.

“We hope this positive collaboration can continue to create more innovations in the future. We also expect that IndoVac can also be distributed overseas, apart from being used in Indonesia, so we can help other countries in need and contribute to global vaccine equality,” commented Honesti Basyir, the President Director of Bio Farma, in a press release issued on September 30, 2022.

 PT Bio Farmais currently manufacturing IndoVac primary series vaccines, while a booster vaccine is in the clinical trial stage.

“The need for a safe, effective, low-cost vaccine for middle- to low-income countries is central to the world’s fight against the COVID-19 pandemic,” added Dr. Maria Elena Bottazzi, co-director of the Texas Children’s Hospital CVD and associate dean of the National School of Tropical Medicine at Baylor.

“Without widespread inoculation of populations in the developing world, which must include safe, effective booster doses, additional variants will develop, hindering the progress achieved by currently available vaccines in the USA and other Western countries.”

In 2022, Biological E. Limited licensed a similar vaccine technology from BCM Ventures to create the CorbeVax vaccine, which is available in India and Botswana.

Note: This announcement was manually translated and curated for mobile readership.

Sep 30, 2022 • 5:03 am CDT
U.S. CDC 2022

The U.S. Centers for Disease Control and Prevention (CDC) Laura Adams, DVM, MPH, and Liliana Sánchez-González, MD, MPH, presented 'What Clinicians Need to Know about Dengue in the United States' during the Clinician Outreach and Communication Activity Call on September 29, 2022.

The CDC insights are essential since dengue is endemic in six U.S. territories and freely associated states, such as Puerto Rico.

In 2022, the CDC confirmed 311 dengue cases in the U.S. States and 145 cases by Territories.

Furthermore, five locally-acquired dengue cases have recently been confirmed in south Florida.

Additionally, the CDC encourages healthcare providers to recognize the three dengue phases (febrile, critical, convalescent) and the severity levels of symptomatic dengue (dengue, dengue with warning signs, severe dengue) based on a patient's clinical and laboratory findings.

Dengue is caused by one of four related viruses.

For this reason, a person can be infected with a dengue virus as many as four times during their lifetime.

Each year, up to 400 million people get infected with dengue worldwide, and 40,000 die from severe dengue, says the CDC.

Dengue viruses are spread to people through the bite of an infected Aedes mosquito.

The CDC confirmed three doses of the U.S. FDA-approved Dengvaxia™ vaccine are indicated for the prevention of dengue in people 9–16 years old with laboratory confirmation of previous dengue virus infection and living in dengue-endemic areas. 

And Takeda's QDENGA® vaccine was recently approved in Indonesia.

QDENGA is the only dengue vaccine approved for use in individuals regardless of previous dengue exposure and without needing pre-vaccination testing. 

Additional dengue vaccine news is posted at Vax-Before-Travel.

Sep 30, 2022 • 4:15 am CDT
by Gerd Altmann

The UK Health Security Agency (UKHSA) today announced it is urging parents and guardians to ensure their children are up to date with all their routine childhood immunizations.

This news shows that most childhood vaccination coverage for young children fell in 2021.

The latest vaccination statistics from UKHSA and NHS Digital for children up to five years of age decreased for 13 of the 14 routine vaccination programs measured from 2021 to 2022.

Low polio vaccination rates in parts of London have left communities vulnerable to the spread of poliovirus, which has been detected in parts of North and East London through sewage surveillance.

As of September 29, 2022, no clinical polio cases have been identified in London.

A polio catch-up vaccination campaign is underway in London for under-vaccinated 1- to 9-year-olds and as a booster dose for certain people.

Dr. Vanessa Saliba, Consultant epidemiologist at UKHSA, said in a related media release, "I would urge parents to check that all children are up to date with their vaccines, and if not, to get them booked in as soon as possible to make sure they have maximum protection against what can be terrible diseases."

"Childhood vaccines also boost population immunity levels, helping prevent outbreaks, so by taking up all vaccinations for our children, we play our part in keeping these diseases confined to the past."

Recently, the WHO reaffirmed that the risk of international spread of poliovirus remains a Public Health Emergency of International Concern.

On September 13, 2022, the USA was added to the list of countries where circulating vaccine-derived poliovirus had been confirmed. 

Furthermore, poliovirus detection in wastewater systems throughout the greater New York City area has been related to London's detections.

In the USA, polio vaccines are generally available at most clinics and pharmacies.

Other polio outbreak news is posted at